Rare t-cell lymphomas

Rare Hematological Malignancies

Volumn , Issue , 2008, Pages 331-347

  Molina, Ana Maria ^a   Horwitz, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; INTESTINE TUMOR; LIVER TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SKIN TUMOR; SPLEEN TUMOR; T CELL LYMPHOMA;

HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LYMPHOMA, T-CELL; SKIN NEOPLASMS; SPLENIC NEOPLASMS;

EID: 40549122036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73744-7_14     Document Type: Chapter

References (106)

1. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18(4):795-803.
2. Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma: a single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995;21:123-129.
3. Morton JE, Leyland MJ, Vaughan HG, et al. Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases. Br J Cancer 1993;67:776-782.
4. Holmes G K T, Prior P, Lane MR, et al. Malignancy in celiac disease: effect of a gluten free diet. Gut 1989;30:333-338.
5. Okada M, Maeda K, Suzumiya J, et al. Primary colorectal T-cell lymphoma. J Gastroenterol 2003;38:376-384.
6. Kluin PM, Feller A, Gaulard P, et al. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology 2001;38:250-270.
7. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003;40(3):175-184.
8. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC Press; 2001.
9. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+ CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998;153:1483-1490.
10. Isaacson PG, Wright DH. Intestinal lymphoma associated with malabsorption. Lancet 1978;311(8055):67-70.
11. Holmes GK. Coeliac disease and malignancy. Dig Liver Dis 2002;34:229-337.
12. Cooke CB, Krenacs M, Stetler-Stevenson M, et al. Hepatosplenic gamma/delta T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma/delta T-cell origin. Blood 1996;88:4265-4274.
13. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475.
14. Wohrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathytype intestinal T-cell lymphoma. Ann Oncol 2004;15:1680-1683.
15. Daum S, Ullrich R, Heise W et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003;21:2740-2746.
16. Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J 2004;5(Suppl 1):50-61.
17. Isaacson PG, O'Connor NT, Spencer J, et al. Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet 1985;2:688-691.
18. Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002;161:1635-1645.
19. Catassi C, Fabiana E, Corrao G, et al. Risk of non-Hodgkin's lymphoma in celiac disease. JAMA 2002;287:1413-1419.
20. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
21. Halfdanarson TR, Litzow MR, Murray JA. Hematological manifestations of celiac disease. Blood 2007;109:412-421.
22. Anon. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
23. Isaacson PG, Du M. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol 2005;205:255-274.
24. Isaacson PG. Gastrointestinal lymphomas of T- and B-cell types. Mod Pathol 1999;12(2):151-158.
25. Obermann EC, Diss TC, Hamoudi RA, et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol 2004;202:252-262.
26. Wei S, Liu T, Wang D, et al. Hepatosplenic γ/δ T-cell lymphoma. World J Gastroenterol 2005;11(24):3729-3734.
27. Farcet J, Gaulard P, Marolleau J, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor γδ. Blood 1990;75:2213-2219.
28. Weidmann E. Hepatosplenic T cell lymphoma. A review of 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000;14:991-997.
29. Pan L, Diss TC, Peng H, et al. Epstein-Barr virus (EBV) in enteropathy-associated T-cell lymphoma (EATL). J Pathol 1993;170:137-143.
30. De Bruin PC, Jiwa NM, Van der Valk P, et al. Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein-1 positivity and clinical course. Histopathology 1993;23:509-518.
31. De Bruin PC, Jiwa NM, Oudejans JJ, et al. Epstein-Barr virus in primary gastrointestinal T cell lymphomas. Association with gluten-sensitive enteropathy, pathological features, and immunophenotype. Am J Pathol. 1995;146:861-867.
32. Weisenburger DD, Wilson WH, Vose JM. Peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic study of 340 cases from the International T-Cell Lymphoma Project. Blood (ASH Annual Meeting Abstracts) 2006;108:2458.
33. Fairley NH, Mackie FP. The clinical and biochemical syndrome in lymphoma and allied diseases involving the mesenteric lymph glands. Br Med J 1937;1:375-380.
34. Catassi, C, Bearzi, Holmes G. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005;128:S79-S86.
35. Howdle PD, Jalal PK, Holmes G K T, et al. Primary small bowel malignancy in the UK and its association with coeliac disease. Q J Med 2003;96:345-353.
36. Verkarre V, Romana S, Cellier C, et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003;125:40-46.
37. Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006;47:1622-1627.
38. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005;153:874-880.
39. Go RS, Gazelka H, Hogan JD, et al. Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine. Ann Hematol 2003;82:247-250.
40. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma. A systematic analysis of 156 patients reported in the literature. Cancer 2004;101:1404-1413.
41. Jaffe ES, Ralfkiaer E. Subcutaneous panniculitis-like T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumors: pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, p. 212-215.
42. Gonzalez CL, Medeiros J, Braziel RM, et al. T-Cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.
43. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003;101:3407-3412.
44. Toro JR, Beaty M, Sorbara L, et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol 2000;136:1024-1032.
45. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 2004;28:719-735.
46. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for the Research and Treatment of Cancer. Blood 1997;90:354-371.
47. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol 2001;23:206-215.
48. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
49. Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003;148:516-525.
50. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-893.
51. Hoffmann M, Vogelsang H, Kletter K, et al. 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003;52:347-351.
52. Moleti ML, Testi AM, Giona F, et al. Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone. Leuk Lymphoma. 2006;47:333-336.
53. Przybylski GK, Wu H, Macon WR, et al. Hepatosplenic and subcutaneous panniculitis-like γ/δ T cell lymphomas are derived from different Vd subsets of γ/δ T lymphocytes. J Mol Diagn 2000;2:11-19.
54. Morice WG, Macon WR, Dogan A, et al. NK-Cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia. 2006;20:883-886.
55. Hassan R, Franco SA, Stefanoff CG, et al. Hepatosplenic gamma delta T-cell lymphoma following seven malaria infections. Pathol Int 2006;56:668-673.
56. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
57. Belhadj K, Reyes F, Farcet J, et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-4269.
58. Motta G, Vianello F, Menin C, et al. Hepatosplenic gammadelta T-cell lymphoma presenting with immune-medicated thrombocytopenia and hemolytic anemia (Evan's syndrome). Am J Hematol 2002;69:272-276.
59. Chen JH, Chan DC, Lee HS, et al. Spontaneous splenic rupture associated with hepatosplenic gammadelta T-cell lymphoma. J Formos Med Assoc 2005;104:593-596.
60. Kumar S, Lawlor C, Jaffe ES. Hepatosplenic T-cell lymphoma of alphabeta lineage. Am J Surg Pathol 2001;25:970-971.
61. Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998;114:471-481.
62. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 2000;356:203-208.
63. Daum S, Weiss D, Hummel R, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut 2001;49:804-812.
64. Smedby KE, Akerman M, Hildebrand H, et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005;54:54-59.
65. Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep 2006;16:191-195.
66. Al-Toma A, Goerres MS, Meijer JW, et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006;4:315-319.
67. Quintanilla-Martinez L, Lome-Maldonado C, Ott G, et al. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. Blood 1997;89:644-651.
68. Honemann D, Prince HM, Hicks RJ, et al. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol 2005;84:118-121.
69. Al-toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood 2007;109(5):2243-2249.
70. Al-toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006;11:1322-1327.
71. Rongey C, Micallef I, Smyrk T, et al. Successful treatment of enteropathy-associated T-cell lymphoma with autologous stem cell transplant. Dig Dis Sci 2006;51:1082-1086.
72. Bishton M, Andrew H. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2006;136:111-113.
73. Vivas S, Ruiz de Morales JM, Ramos F, et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006;354:2514-2515.
74. Verbeek W, Mulder C, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med 2006;355:1396-1397.
75. Lundin KE, Farstad IN, Raki M, et al. Alemtuzumab treatment of refractory celiac disease type II (Abstract). Gastroenterol 2006;130(Suppl 2):A-666.
76. Au W Y, Ng WM, Choy C, et al. Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol 2000;143:408-410.
77. Reimer P, Rudiger T, Muller J, et al. Subcutaneous panniculitis-like T-cell lymphoma during pregnancy with successful autologous stem cell transplantation. Ann Hematol 2003;82:305-309.
78. Mukai HY, Okoshi Y, Shimizu S, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol 2003;70:413-416.
79. Ghobrial I, Weenig R, Pittlekow MR, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 2005;46:703-708.
80. De Wolf-Peeters C, Achten R. γδ T-cell lymphomas: a homogenous entity? Histopathology 2000;36:294-305.
81. Kumar S, Krenac, L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998;29:397-403.
82. Takeshita M, Imayama S, Oshiro Y, et al. Clinicopathologic analysis of 22 cases of subcutaneous panniculitis-like CD56- or CD56+ lymphoma and review of 44 other reported cases. Am J Clin Pathol 2004;121:408-416.
83. Willemze R, Jaffe E, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
84. Horwitz S, Foss F, Goldfarb S, et al. FDG-PET scans as an additional staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood (ASH Annual Meeting Abstracts) 2006;108:2399.
85. Suarez F, Wlodarska I, Rigal-Huquet F, et al. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical histologic and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol 2000;24:1027-1032.
86. Joyce AM, Burns DL, Marcello PW, et al. Capsule endoscopy findings in celiac disease associated enteropathy-type intestinal T-cell lymphoma. endoscopy 2005;37:594-596.
87. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas report of the EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-627.
88. Bekkenk MW, Jansen PM, Meijer C J L M, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15:1097-1108.
89. Ichii M, Hatanaka K, Imakita M, et al. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk Lymphoma 2006;47:2250-2252.
90. Leo E, Bertz H, Koehler G, et al. Successful treatment of aggressive, recurrent, subcutaneous panniculitis-like T cell lymphoma (SPTCL) with high-dose chemotherapy followed by allogeneic peripheral stem cell transplantation (Abstract). Blood 2001;98:377b.
91. Tsukamato Y, Katsunobu Y, Omura Y, et al. Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A. Intern Med 2006;45:21-24.
92. Al Zolibani AA, Al Robaee AA, Qureshi MG, et al. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A. Skinmed 2006;5:195-197.
93. Molina A, Advani R, Reddy S, et al. Bexarotene is highly active in the treatment of subcutaneous panniculitis-like T-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2005 106:3344.
94. McFarlane V, Friedman PS, Illidge TM. What's new in the management of cutaneous T-cell lymphoma? Clin Oncol 2005;17:174-184.
95. Romero LS, Goltz RW, Nagi C, et al. Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. J Am Acad Dermatol. 1996;34:904-910.
96. Munn SE, McGregor JM, Jones A, et al. Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Br J Dermatol. 1996;135:976-981.
97. Haycox CL, Back AL, Raugi GJ, et al. Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation. J Am Acad Dermatol 1997;37:832-825.
98. Koizumi K, Sawada K, Nishio M, et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant 1997;20:171-173.
99. Dargent JL, Roufosse C, Delville JP, et al. Subcutaneous panniculitis-like T-cell lymphoma: further evidence for a distinct neoplasm originating from large granular lymphocytes of T/NK phenotype. J Cutan Pathol 1998;25:394-400.
100. Magro CM, Crowson AN, Kovatich AJet al. Lupus profundus, indeterminate lymphocytic lobular panniculitis and subcutaneous T-cell lymphoma: a spectrum of subcuticular T-cell lymphoid dyscrasia. J Cutan Pathol 2001;28:235-247.
101. Ferrari D, Girmenia G, Migliorini L, et al. Hepatosplenic gamma delta T-cell lymphoma with a novel cytogenetic alteration and cerebrospinal fluid infiltration: biological and clinical features. Haematologica 2002;87:ERC11.
102. Khan WA, Yu L, Eisenbrey AB, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients report: Report of two cases and review of literature. Am J Clin Pathol 2001;116:41-50.
103. Francois A, Lesesve JF, Stamatoullas A, et al. Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 1997;21:781-790.
104. Kraus MD, Crawford DF, Kaleem Z, et al. T Gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report. Cancer. 1998;82:983-992.
105. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-111.
106. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991;5:983-1001.